Pharmacological Predictors of Successful Cyclosporine Acute GVHD Prophylaxis in Children Undergoing HSCT

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

105 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-10-31

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The specific objectives of this study are:

Primary:

1)To determine the relationship between cyclosporine AUC achieved prior to engraftment and severe aGVHD (grade III and IV)

Secondary:

1. To determine the relationship between individual concentration-time points achieved prior to engraftment and severe aGVHD (grade III and IV)
2. To validate the previously developed LSS to determine cyclosporine AUC after IV administration at steady state and
3. To describe the relationship between cyclosporine AUC and individual concentration-time points achieved prior to engraftment and other HSCT outcomes (clinically significant aGVHD (grade II to IV), hypertension, engraftment failure, relapse

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacokinetic Study of Post-transplant Cyclophosphamide in Pediatric Patients

NCT04945954

Hematopoietic Stem Cell Transplantation

UNKNOWN NA

Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention

NCT06926595

Graft-versus-Host Disease (GVHD) Hematologic Malignancies Allogeneic Stem Cell Transplantation

NOT_YET_RECRUITING PHASE2

Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy

NCT03555851

Leukemia, Not Otherwise Specified Leukemia, Other

RECRUITING

Upfront Ruxolitinib for Chronic Graft-vs-host Disease

NCT06695507

Chronic Graft Versus Host Disease

RECRUITING PHASE1

Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD

NCT05621759

Graft Vs Host Disease

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute-graft-versus-host Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* less than 18 years of age
* undergoing allogeneic myeloablative HSCT at one of the participating centres and
* scheduled to receive cyclosporine for aGVHD prophylaxis
* minimum patient weight:
* 6.4kg if \< 6 months old or 7.2kg if \> 6 months old

All patients or guardians will provide informed consent or assent as appropriate. Initial contact will be made by a member of the patient's current care team. Consent will be obtained by a co-investigator or the CTSU personnel.